Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | PHI-101 |
| Synonyms | |
| Therapy Description |
PHI-101 is a Chk2 inhibitor with additional activity against FLT3, which potentially results in antitumor activity (Cancer Res 2021;81(13_Suppl):Abstract nr 1461, Cancer Res 2020;80(16 Suppl):Abstract nr 4226). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PHI-101 | PHI101|PHI 101 | CHK2 Inhibitor 7 FLT3 Inhibitor 65 | PHI-101 is a Chk2 inhibitor with additional activity against FLT3, which potentially results in antitumor activity (Cancer Res 2021;81(13_Suppl):Abstract nr 1461, Cancer Res 2020;80(16 Suppl):Abstract nr 4226). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins | acute myeloid leukemia | predicted - sensitive | PHI-101 | Preclinical - Patient cell culture | Actionable | In a preclinical study, PHI-101 decreased proliferation and induced apoptosis in patient-derived acute myeloid leukemia samples harboring a FLT3-ITD mutation in culture (Blood (2020) 136 (Supplement 1): 802). | detail... |
| FLT3 exon 14 ins FLT3 F691L FLT3 D835Y | hematologic cancer | predicted - sensitive | PHI-101 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PHI-101 decreased leukemia burden in a cell line xenograft model expressing FLT3 D835Y and F691L in the context of a FLT3-ITD mutation (Blood (2020) 136 (Supplement 1): 802). | detail... |
| FLT3 exon 14 ins FLT3 D835A | hematologic cancer | predicted - sensitive | PHI-101 | Preclinical - Biochemical | Actionable | In a preclinical study, PHI-101 demonstrated activity against FLT3 D835A in the context of a FLT3-ITD mutation in culture (Cancer Res 2020;80(16 Suppl):Abstract nr 4226). | detail... |
| FLT3 exon 14 ins FLT3 D835Y | hematologic cancer | predicted - sensitive | PHI-101 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PHI-101 decreased leukemia burden in a cell line xenograft model expressing FLT3 D835Y in the context of a FLT3-ITD mutation (Blood (2020) 136 (Supplement 1): 802). | detail... |
| FLT3 exon 14 ins FLT3 F691L | hematologic cancer | predicted - sensitive | PHI-101 | Preclinical - Biochemical | Actionable | In a preclinical study, PHI-101 demonstrated activity against FLT3 F691L in the context of a FLT3-ITD mutation in culture (Cancer Res 2020;80(16 Suppl):Abstract nr 4226). | detail... |
| FLT3 exon 14 ins FLT3 F691L | hematologic cancer | predicted - sensitive | PHI-101 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PHI-101 decreased leukemia burden in a cell line xenograft model expressing FLT3 F691L in the context of a FLT3-ITD mutation (Blood (2020) 136 (Supplement 1): 802). | detail... |
| FLT3 exon 14 ins FLT3 N676D | hematologic cancer | predicted - sensitive | PHI-101 | Preclinical - Biochemical | Actionable | In a preclinical study, PHI-101 demonstrated activity against FLT3 N676D in the context of a FLT3-ITD mutation in culture (Cancer Res 2020;80(16 Suppl):Abstract nr 4226). | detail... |
| FLT3 exon 14 ins FLT3 A627T | hematologic cancer | predicted - sensitive | PHI-101 | Preclinical - Biochemical | Actionable | In a preclinical study, PHI-101 demonstrated activity against FLT3 A627T in the context of a FLT3-ITD mutation in culture (Cancer Res 2020;80(16 Suppl):Abstract nr 4226). | detail... |
| FLT3 exon 14 ins | hematologic cancer | predicted - sensitive | PHI-101 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PHI-101 induced tumor regression in a cell line xenograft model expressing a FLT3-ITD mutation (Blood (2020) 136 (Supplement 1): 802). | detail... |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST